Rearrangements of Bcl-1, Bcl-2, Bcl-6, and C-Myc in Diffuse Large B-Cell Lymphomas

References

• Gaynor E. R., Fisher R. I. Diffuse aggressive lymphomas in adults. The Non-Hodgkin's Lymphomas, I.T. Magrach. Williams & Wilkins, Baltimore 1990; 317–329
   Google Scholar
• Ohshima K., Suzumiya J., Sato K., Kanda M., Haraoka S., Kikuchi M. B-cell lymphoma of 708 cases in Japan; incidence rate and clinical prognosis according to REAL classification. Cancer Letters 1999; 135: 73–81
   PubMed Web of Science ®Google Scholar
• Haris N. L., Jaffe E. S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factor Project. A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Gascoyne R. D., Adomat S. A., Krajewski S., et al. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244–251
   PubMed Web of Science ®Google Scholar
• Kramer MHH., Hermans J., Parker J., et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J. Clin. Oncol 1996; 14: 2131–2138
   PubMed Web of Science ®Google Scholar
• Offit K., Lo Coco F., Louie DC., et al. Rearrangement of bcl6 gene as a prognostic marker in diffuse large-cell lymphoma. N. Engl. J. Med. 1994; 331: 74–80
   PubMed Web of Science ®Google Scholar
• Pris MA., Pezella F., Martinez-Montero JC., et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br. J. Cancer 1994; 69: 337–341
   PubMed Web of Science ®Google Scholar
• Sanchez E., Chacon I., Plaza MM., et al. Clinical outcome in diffuse large B-cell Lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J. Clin. Oncol. 1998; 16: 1931–1993
   PubMed Web of Science ®Google Scholar
• Wilson WH., Teruya-Peldestein J., Fest T., et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89: 601–609
   PubMed Web of Science ®Google Scholar
• Kerckaert JP., Deweindt C., Tilly H., Quief S., Lecocq G., Bastard C. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphoma. Nat Genet 1993; 5: 66–70
   PubMed Web of Science ®Google Scholar
• Yunis JJ., Frizzera G., Oken M., et al. Multiple recurrent genomic defects in follicular lymphoma: A possible model for cancer. N. Engl. J. Med. 1987; 16: 79–84
   Web of Science ®Google Scholar
• Butler M., Corbally N., Dervan PA., Carney DN. BCL-6 and other genomic alterations in non-Hodgkin's lymphoma(NHL). Br. J. Cancer 1997; 75: 1641–1645
   PubMed Web of Science ®Google Scholar
• Kramer M. H.H., Hermans J., et al. Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-cell Lymphoma. Blood 1998; 92: 3152–3162
   PubMed Web of Science ®Google Scholar
• Vitolo U., Gaidano G., et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patients. Ann. Oncol. 1998; 9: 55–61
   PubMed Web of Science ®Google Scholar
• Lo Coco F., Ye BH., Lista F., et al. Rearrangements of the bcl-6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1989; 74: 1876–9
   PubMedGoogle Scholar
• Baldin V., Lukas J. Marcote, Pagano M. Draetta. G. Cyclin-D1 is a nuclear protein required for cell for cell cycle progression G1. Genes Dev. 1993; 7: 812–821
   PubMed Web of Science ®Google Scholar
• Yatabe Y., Nakamura S., Seto M., et al. Clinicopathologic study of PRAD/CyclinD1 overexpressing lymphoma with special Reference to mantle cell lymphoma. Am. J. Surg. Pathol. 1996; 20: 1110–1122
   PubMed Web of Science ®Google Scholar
• Bastard C., Deweindt C., Kerckaert J. P., et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994; 83: 2423–2427
   PubMed Web of Science ®Google Scholar
• Ye B. H., Lista F., Lo Coco F., et al. Alterations of a zinc fingerencoding gene, BCL6, in diffuse large-cell lymphoma. Science 1993; 262: 747–750
   PubMed Web of Science ®Google Scholar
• Muramatsu M., Akasaka T., Kadowaki N., et al. Rearrangements of BCL-6 gene in B-cell lymphoid neoplasms: Comparison with lymphomas associated with BCL-2 rearrangement. Br. J. Haematol. 1997; 93: 911–920
   Web of Science ®Google Scholar
• Hutchison R., Murphy S., Fairclough D., et al. Diffuse small non-cleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types. Cancer 1989; 64: 23–28
   PubMed Web of Science ®Google Scholar
• Zhang A., Ohshima K., et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathology International 1999; 49: 1043–1052
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. National cancer Institut-sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–35
   PubMed Web of Science ®Google Scholar
• Van Krieken JHJM, Raffeld M., Rabhoeber S., Jaffe ES., Van Ommen GJB, Kluin PM. Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: Unusual prevalence and pattern of MYC rearrangements in aggressive lymphomas. Blood 1990; 76: 797–800
   PubMed Web of Science ®Google Scholar
• Hall PA., Richards MA., Gregory WM., Ardenne AJ., Lister TA., Atansfeld AG. The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphoma. J. Patholl 1998; 154: 223–235
   Web of Science ®Google Scholar
• Ince C., Buck M., Lee M., Pathak S., Vadhan-Raj S., Selvenay-Agam P., Gutterman JU, Cabanillas F. Bcl-1 gene rearrangements in B cell lymphomas. Leukemia 1988; 2: 343–346
   PubMed Web of Science ®Google Scholar
• Athan E., Foitl DR, Knowles DM. BCL-1 Rearrangement: Frequency and clinical significance among B-cell chronic lymphocytic leukemias and non-Hodgkin's lymphomas. Am. J. Pathol 1991; 138: 591–599
   PubMed Web of Science ®Google Scholar
• Hill ME., MacLennan KA., Cunningham D., Hudson BV, Burke M., Clarke P., Di Stefano F., Anderson L., Hudson GV., Mason D., Selby P., Linch DC. Prognostic significance of BCL2 expression and BCL2 major breakpoint lesion rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood 1996; 88: 1046–51
   PubMed Web of Science ®Google Scholar
• Offit K., Koduru PRK., Hollis R., Filippa D., Jhanwar SC., Clalson BC., Chagani RSK. 18q21 rearrangements in diffuse large cell lymphoma: Incidence and clinical significance. Br. J. Haematology 1989; 72: 178–83
   PubMed Web of Science ®Google Scholar
• Tang SC., Visser L., Hepperle B., Hanson J., Poppema S. Clinical significance of BCL2 mbr gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases. J Clin Oncol 1994; 12: 149–154
   PubMed Web of Science ®Google Scholar
• Yunis JJ., Mayer MG., Arnesen MA., Aeppli DP., Oken MM., Frizzera G. BCL2 and other genomic alterations in the prognosis of large cell lymphoma. N Engl I Med 1989; 320: 1047–1054
   PubMed Web of Science ®Google Scholar
• Ohshima K., Kikuchi M., Kobari F., Eguchi F., et al. Bcl-2 Gene and Prognosis of B-cell Lymphoma. Leukemia and Lymphoma 1991; 5: 305–310
   PubMed Web of Science ®Google Scholar
• The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathology international 2000; 50: 696–702
   PubMed Web of Science ®Google Scholar
• Dalla-Favera R., Yye BH., Le Coco F., Gaidano G., Lista F., Knowles DM., Louie DC., Offit K., Chaganti RSK. Identification of genetic lesions associated with diffuse large-cell lymphoma. Ann Oncol (Suppl) 1994; 5: S55–S60
   Web of Science ®Google Scholar
• Dalla-Favera R., Bregui M., Erikson J., Patterson D., Galoc RC., Croce CM. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824–7
   PubMed Web of Science ®Google Scholar
• Erikson J., Nishikura K., Al-Rushdi A., et al. Translocation of an immunoglobulin K locus to a region 3′ of an unrearranged c-myc oncogene enhances c-myc transcription. Proc Natl Acad Sci USA 1983; 80: 7581–5
   PubMed Web of Science ®Google Scholar
• Neri A., Barriga F., Knowles D., Magrath I., Della-Fevera R. Different regions of the immunoglobulin heavy chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci USA 1988; 85: 2748–52
   PubMed Web of Science ®Google Scholar
• Van Krieken JHJM., Medeiros J., Pals ST., Raffeld M., Kluin PM. Diffuse aggressive B-cell lymphomas of the gastrointestinal tract: An immunophenotypic and rearrangement analysis of 22 cases. Am J Clin Pathol 1992; 97: 170–178
   PubMed Web of Science ®Google Scholar
• Yunis JJ., Oken MM., Theologides A., Howe RB., Kaplan ME. Recurrent chromosomal defects are found in most patients with non-Hodgkin's lymphoma. Cancer Genet Cytogenet 1984; 13: 17–28
   PubMed Web of Science ®Google Scholar